Jenrin Discovery, Inc.
Records under this name other than the patents Jenrin Discovery, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 10 patents it holds.
Back to Jenrin Discovery, Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,987,253 | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes Lapsed on the fee record Ended Jun 5, 2026 · From the USPTO record | Lapsed on the fee record | Ended Jun 5, 2026 | From the USPTO record |
| US 8,680,131 | Cannabinoid receptor antagonists/inverse agonists useful for treating disease conditions, including metabolic disorders and cancers Lapsed on the fee record Ended Mar 25, 2026 · From the USPTO record | Lapsed on the fee record | Ended Mar 25, 2026 | From the USPTO record |
| US 11,179,370 | Cannabinoid receptor antagonists/inverse agonists useful for treating disease conditions, including metabolic disorders and cancers Lapsed on the fee record Ended Nov 23, 2025 · From the USPTO record | Lapsed on the fee record | Ended Nov 23, 2025 | From the USPTO record |
| US 9,517,228 | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes Lapsed on the fee record Ended Dec 13, 2024 · From the USPTO record | Lapsed on the fee record | Ended Dec 13, 2024 | From the USPTO record |
| US 10,617,673 | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes Lapsed on the fee record Ended Apr 14, 2024 · From the USPTO record | Lapsed on the fee record | Ended Apr 14, 2024 | From the USPTO record |
| US 8,088,809 | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes Lapsed on the fee record Ended Jan 3, 2024 · From the USPTO record | Lapsed on the fee record | Ended Jan 3, 2024 | From the USPTO record |
| US 9,133,127 | Cannabinoid receptor antagonists/inverse agonists useful for treating disease conditions, including metabolic disorders and cancers Lapsed on the fee record Ended Sep 15, 2023 · From the USPTO record | Lapsed on the fee record | Ended Sep 15, 2023 | From the USPTO record |
| US 8,716,265 | 4-quinolinemethanols as anti-malarial agents Lapsed on the fee record Ended May 6, 2018 · From the USPTO record | Lapsed on the fee record | Ended May 6, 2018 | From the USPTO record |
| US 7,687,481 | Cannabinoid receptor antagonists/inverse agonists useful for treating obesity Lapsed on the fee record Ended Mar 30, 2018 · From the USPTO record | Lapsed on the fee record | Ended Mar 30, 2018 | From the USPTO record |
| US 7,649,115 | MAO-B inhibitors useful for treating obesity Lapsed on the fee record Ended Jan 19, 2018 · From the USPTO record | Lapsed on the fee record | Ended Jan 19, 2018 | From the USPTO record |